BBO-10203

Other Medications

Experimental

Not available 2 Clinical Trials

Description

BBO-10203 is an experimental drug being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is currently in Phase 1 trials, which means researchers are primarily looking at its safety and determining the right dosage. These trials are open-label, meaning both the researchers and the patients know which treatment is being given. BBO-10203 is being tested both by itself and in combination with other cancer drugs like Trastuzumab, Fulvestrant, Ribociclib, FOLFOX (5-Fluorouracil, Leucovorin, Oxaliplatin), and Bevacizumab. The trials are enrolling patients with advanced colorectal cancer and other solid tumors. The specific types of genetic changes (like BRAF, EGFR, HER2, KRAS, NTRK1 mutations) that might make a patient eligible for these trials are being explored.

Mechanism of Action

The specific way BBO-10203 works (its mechanism of action) is still being investigated in these early clinical trials. Researchers are studying how it affects the body and its potential impact on tumor cells. It is being tested as a single agent and in combination with other therapies to see how it might fight cancer.

Side Effects

Because BBO-10203 is in Phase 1 trials The full range of potential side effects is still being evaluated. Researchers are carefully monitoring patients in the trials to assess the drug's safety and tolerability. Common side effects for drugs in this class or used in combination (like FOLFOX Bevacizumab Trastuzumab Ribociclib Fulvestrant) can include fatigue Nausea Diarrhea Hair loss Skin reactions And changes in blood counts But the specific side effects related to BBO-10203 are still being determined.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06917079 Phase 1

Recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

United States, Australia

NCT06625775 Phase 1

Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

United States, Australia, Brazil, France, Spain

Quick Info

Category	Other Medications
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	2

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.